To the Editor Schoenfeld et al1 presented nivolumab plus ipilimumab (N+I) combination as a feasible neoadjuvant treatment in patients with untreated oral cavity squamous cell carcinoma (OCSCC). In this trial, unvalidated efficacy end points and immature data of clinically relevant outcomes (progression-free survival and overall survival) were described. No dose-limiting toxic effects or surgical delays were observed in the N+I cohort. However, other safety data could have significant clinical implications.